

Role of *STK11* in *ALK*-positive non-small cell lung cancer (Review)

WEN ZHOU^{1*}, LU-DA YAN^{1*}, ZHI-QIONG YU¹, NA LI¹, YONG-HUA YANG¹, MENG WANG¹,
YUAN-YUAN CHEN¹, MENG-XIA MAO¹, XIAO-CHUN PENG^{2,3} and JUN CAI¹

¹Department of Oncology, First Affiliated Hospital of Yangtze University; ²Laboratory of Oncology,
Center for Molecular Medicine; ³Department of Pathophysiology, School of Basic Medicine,
Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China

Received January 17, 2022; Accepted April 1, 2022

DOI: 10.3892/ol.2022.13301

Abstract. Anaplastic lymphoma kinase (*ALK*) inhibitors have been shown to be effective in treating patients with *ALK*-positive non-small cell lung cancer (NSCLC), and crizotinib, ceritinib and alectinib have been approved as clinical first-line therapeutic agents. The availability of these inhibitors has also largely changed the treatment strategy for advanced *ALK*-positive NSCLC. However, patients still inevitably develop resistance to *ALK* inhibitors, leading to tumor recurrence or metastasis. The most critical issues that need to be addressed in the current treatment of *ALK*-positive NSCLC include the high cost of targeted inhibitors and the potential

for increased toxicity and resistance to combination therapy. Recently, it has been suggested that the serine/threonine kinase 11 (*STK11*) mutation may serve as one of the biomarkers for immunotherapy in NSCLC. Therefore, the main purpose of this review was to summarize the role of *STK11* in *ALK*-positive NSCLC. The present review also summarizes the treatment and drug resistance studies in *ALK*-positive NSCLC and the current status of *STK11* research in NSCLC.

Contents

1. Introduction
2. Current research advances in *ALK*-positive NSCLC
3. Current research progress on *STK11*
4. Conclusions and perspectives

1. Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the most common subtype (1). The majority of patients with NSCLC are diagnosed at an advanced, inoperable stage (2) and have an overall 5-year survival rate of just 5% (3). This poor prognosis may be associated with tumor heterogeneity, acquisition and intrinsic resistance to therapeutic agents in NSCLC (4). If the most appropriate treatment is identified early and drug resistance is addressed to a satisfactory degree, patient survival can be significantly improved. Current non-surgical treatments for NSCLC in clinical practice include systemic chemotherapy, radiotherapy, targeted therapy and immunotherapy (IO). In recent years, rapid developments have been made in cellular and molecular biotechnology, and targeted gene therapy and IO are gradually gaining traction (5). Molecular testing is commonly used in NSCLC, and the detection of epidermal growth factor receptor (*EGFR*), B-Raf proto-oncogene, serine/threonine kinase (*BRAF*) and MET proto-oncogene, receptor tyrosine kinase (*MET*) mutations, as well as anaplastic lymphoma kinase (*ALK*), ROS proto-oncogene 1, receptor tyrosine kinase (*ROS1*), ret proto-oncogene (*RET*) and neurotrophic receptor tyrosine kinase 1 (*NTRK1*) translocations have been incorporated into the diagnostic criteria for NSCLC, and inhibitors of these kinases are now

Correspondence to: Dr Xiao-Chun Peng, Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, P.R. China
E-mail: pxcwd789@sina.com

Dr Jun Cai, Department of Oncology, First Affiliated Hospital of Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, P.R. China
E-mail: 529369023@qq.com

*Contributed equally

Abbreviations: NSCLC, non-small cell lung cancer; *ALK*, anaplastic lymphoma kinase; IR, insulin receptor; ALCL, anaplastic large cell lymphoma; EML4, echinoderm microtubule-associated protein like protein 4; CNS, center nervous system; FDA, food and drug administration; AMPK, amp-activated protein kinase; *EGFR*, epidermal growth factor receptor; MEK, MAP kinase-Erk kinase; ERK, extracellular signal-regulated kinase; NRF2, nuclear related factor 2; NADPH, nicotinamide adenine dinucleotide phosphate; PFS, progression-free survival; OS, overall survival; ORR, objective remission rate; LKB1, liver kinase B1; TMB, tumor mutation burden; ATP, adenosine triphosphate; IO, immunotherapy; *STK11*, serine/threonine kinase 11; *STK11m*, *STK11* mutation; *STK11wt*, *STK11* wild-type; PD-1, programmed death 1; PD-L1, programmed cell death-ligand 1

Key words: non-small cell lung cancer, anaplastic lymphoma kinase-positive, *STK11*, drug resistance, targeted therapies

routinely used in the clinic (6). An increasing number of signaling pathways and driver genes are being identified, and therapeutic drugs for NSCLC are emerging (7,8). Targeted drugs can bind specifically to the oncogenic site and induce cancer cell-specific death (9). Targeted drugs have a higher efficacy and fewer side effects than chemotherapy (10,11). However, each generation of targeted drugs shows different degrees of resistance; therefore, identifying new therapeutic targets following resistance is crucial. Multiple mutations are not uncommon in clinical practice in recent years, and exploring serine/threonine kinase 11 (*STK11*) co-mutations in *ALK*-positive NSCLC patients is important.

A number of recent studies have linked the presence of *STK11* mutations to the lack of response to IO in NSCLC (12-16). In addition, several clinical studies have further elucidated the biological role of *STK11* mutations leading to primary resistance to IO (17-19). The implementation of *STK11* mutations as a routine biomarker in NSCLC remains controversial and is not performed in daily practice (20).

Therefore, the aim of the present study was to investigate the role of *STK11* in *ALK*-positive NSCLC, review the treatment of patients with *ALK*-positive NSCLC, and compare the clinical efficacy, resistance mutations and appropriate resistance solutions of three generations of *ALK* inhibitors.

2. Current research advances in *ALK*-positive NSCLC

ALK and NSCLC. As a receptor tyrosine kinase of the insulin receptor (IR) subfamily, *ALK* has been found to play an important role in various types of cancer, particularly in anaplastic large cell lymphoma (ALCL), NSCLC and neuroblastoma (21). In 2007, the echinoderm microtubule-associated protein like protein 4 (*EML4*)-*ALK* fusion gene was identified in a group of NSCLC patients (22). This fusion is the result of an inversion of the short arm of chromosome 2, where the human *EML4* and *ALK* genes are present (23). *EML4* contains a coiled oligomeric structural domain, which mediates the dimerization and structural activation of *ALK*. Like in ALCL, many different *ALK* fusions have been identified, but *EML4-ALK* is the most common variant (24). *ALK* has been reported to regulate several different pathways involved in cell proliferation and survival, such as the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian targets of rapamycin (mTOR), RAS/RAF/MAP kinase-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK and JAK/STAT pathways (Fig. 1), once it is dimerized and activated by autophosphorylation upon binding to its ligands, pleiotrophin and midkine (25,26). Direct evidence for the oncogenic potential of *EML4-ALK* in lung carcinogenesis has been found in mice. The transgenic overexpression of *EML4-ALK* in type II alveolar cells via the surface activated protein-c or Clara cell secretory protein promoter leads to the rapid development of tumors with features of lung adenocarcinoma (27,28). A total of 3-7% of NSCLC (mainly adenocarcinoma subtypes) cases are characterized by *ALK* rearrangements, which occur in a mutually exclusive manner with *KRAS* and *EGFR* mutations (29,30). Of note, a previous study developed *in vivo* induction models by inducing *EML4-ALK* rearrangement, which leads to lung carcinogenesis. These models have shown a sensitivity to *ALK* inhibition, thus serving as valuable tools to explore

the mechanisms of *EML4-ALK*-induced lung cancer and response to *ALK*-targeted therapy (31). Of note, *ALK*-positive NSCLC patients have a healthy weight, are non-smokers or are young (32).

Current targeted therapies for patients with *ALK*-positive NSCLC. Prior to the discovery of the *EML4-ALK* fusion protein, chemotherapy was the first-line treatment option (33). *ALK* inhibitors have shown potent clinical activity in patients with NSCLC (34). Three generations of *ALK* inhibitors have been approved for clinical use (2). Ten years ago, the first-generation *ALK* inhibitor crizotinib was approved for clinical treatment. Table I documents clinical studies associated with *ALK* inhibitors (35-46). In a series of subsequent clinical trials, crizotinib demonstrated good clinical efficacy, including in 149 patients with NSCLC and *ALK* mutations (PROFILE1001), with an objective remission rate (ORR) of 60.8% and progression-free survival (PFS) of 9.7 months in 143 patients evaluated; several other phases of clinical trials also achieved useful results (35) (Table I). However, since crizotinib cannot easily cross the blood-brain barrier, it leads to brain metastases and resistance in patients (24). The rapid development of resistance during the treatment cycle is the main limiting factor associated with crizotinib (47). Since then, progeny *ALK* inhibitors have demonstrated significant efficacy and better central nervous system (CNS) activity compared with crizotinib (48-50). Among the clinical studies of second-generation *ALK* inhibitors, the ASCEND series was a series of studies evaluating the safety and efficacy of ceritinib. Based on this series, ceritinib was approved by the food and drug administration (FDA) for clinical treatment in 2014, mainly for patients who were intolerant to crizotinib or whose disease progressed after taking crizotinib in *ALK*-positive patients (33). As a result, the FDA approved brigatinib for patients who had failed prior *ALK* inhibitor therapy (33). In the J-Alex study in Japan, alectinib was compared head-to-head with crizotinib. The latest data from this trial demonstrated a PFS of 34.1 and 10.2 months in the alectinib and crizotinib groups, respectively (42). In the global ALEX study, a new record was set with a PFS of 34.8 months for first-line treatment with alectinib (Table I), which was approved for the treatment of pure *ALK*-positive patients based on the results of the randomized phase III ALEX trial. In addition, alectinib was effective in preventing the development of brain metastasis and significantly reduced the risk of CNS progression in patients by 84% (43,44). The ALTA-1L study was a study comparing the efficacy and safety of brigatinib with those of crizotinib as first-line treatment for patients with *ALK*-positive metastatic NSCLC (51). The final results showed that when multiple targeted drugs cause resistance, patients can still benefit from brigatinib. Thus, brigatinib has a unique advantage in follow-up therapy. The third-generation *ALK* inhibitor lorlatinib was found to inhibit both the *ALK* and *ROS1* pathways and overcome the multi-resistance associated with first- and second-generation *ALK* inhibitors, while also crossing the blood-brain barrier (45). Regarding IO, irrespective of the histological type, patients treated with atezolizumab showed a significantly longer overall survival than platinum-based chemotherapy in patients with NSCLC with a high programmed cell death-ligand 1 (PD-L1) expression, with a significantly superior efficacy (52).




Figure 1. Signaling pathway of *EML4-ALK* activation. *EML4*, echinoderm microtubule-associated protein like protein 4; *ALK*, anaplastic lymphoma kinase; *ERK*, extracellular signal-regulated kinase; *PI3K*, phosphatidylinositol-3-kinase; *mTOR*, mammalian targets of rapamycin; *JAK*, Janus kinase; *STAT*, signal transducer and activator of transcription; P, phosphorylated.

Mechanisms of *ALK* inhibitor resistance. Although *ALK* inhibitors are clinically effective, patients still experience various types of drug resistance. This usually occurs in the form of *ALK* kinase structural domain mutations, *ALK* site amplification or activation of 'bypass' signaling pathways, ~1/3 of which are *ALK* kinase structural domain mutations (53). The first mutations identified were the L1196M and C1156Y (54), and L1196M is a residue known as the 'gatekeeper' that controls the entry of small-molecule *ALK* inhibitors into a hydrophobic pocket within the catalytic site and can spatially block inhibitor binding (55). Meanwhile, L1196M is the most common mutation in which patients develop resistance to crizotinib (47), while C1156Y develops resistance through other different mechanisms. Cysteine is similar to the catalytically important α C-helix within the structural domain of *ALK* tyrosine kinase, so its substitution for tyrosine is thought to prevent inhibitor binding by stabilizing the activity of *ALK* (47). Other resistant mutations that map to the same region with the same mechanism of resistance include I151Tins, F1174C/L, L1198P, L1152R/P (47,56,57) and L1171T (12,13,58). Acquired resistance to crizotinib usually emerges after 1 year of treatment. *ALK-E1210K* mutations have been detected in patients treated with crizotinib (14). Other secondary mutations that occur following crizotinib treatment include L1196M, G1269A, G1202R, S1206Y, G1269A, L1152R, D1203N, I1171T, V1180L and C1156Y (13,47). The second-generation *ALK* inhibitors ceritinib, alectinib and brigatinib were found to show a stronger anti-*ALK* activity compared with crizotinib (16). In addition, they exhibited greater CNS permeability and the ability to target multiple secondary *ALK* mutations. The direct application of second-generation *ALK* tyrosine kinase inhibitors has been shown to result in better therapeutic outcomes. In addition to *ALK*, ceritinib inhibits insulin-like growth factor 1 (IGF1), *ROS1* and the IR (17,18). In addition, ceritinib inhibits multiple

Table I. Clinical studies associated with *ALK* inhibitors.

Clinical study	Drug	mPFS (month)	ORR (%)
PROFILE 1001 (35)	Crizotinib	9.7	60.8
PROFILE 1005 (36)	Crizotinib	8.4	54.0
PROFILE 1007 (37)	Crizotinib	7.7	65.0
PROFILE 1014 (38)	Crizotinib	10.9	74.0
ASCEND-1 (39)	Ceritinib	18.4	72.0
ASCEND-2 (40)	Ceritinib	5.7	38.6
ASCEND-4 (41)	Ceritinib	16.6	72.5
J-ALEX (42)	Alectinib	34.1	92.0
ALEX (43,44)	Alectinib	34.8	82.9
ALTA-1L (45)	Brigatinib	24.0	71.0
B7461001 (46)	Lorlatinib	9.6	46.0

ALK, anaplastic lymphoma kinase; mPFS, median progression-free survival; ORR, objective response rate.

ALK mutations resistant to crizotinib, including L1196M, G1269A and S1206Y (47). However, C1156Y/T, I1151Tins and L1152P/R mutations have been associated with the emergence of ceritinib resistance (19). Alectinib has a better efficacy against G1269A, L1196M, F1174L and C1156Y mutations (20); however, alectinib treatment has been shown to cause the emergence of resistance mutations (I1171T/N/S, V1180L and G1202R) (14,58), and the activated bypass signaling pathway to be mediated by hepatocyte growth factor (HGF) and *MET* (59). Epithelial-mesenchymal transition (EMT) is a potential mechanism of alectinib resistance, characterized by the loss of E-cadherin and increased expression of waveform proteins (60). Brigatinib is a novel inhibitor of *ALK*, *ROS1* and *EGFR*. Brigatinib inhibits crizotinib-resistant mutations, including *ALK* L1196M and *EGFR* T790M (51). Lorlatinib can be used to treat all known *ALK* inhibitor-induced resistance mutations and is the treatment of choice for patients with alectinib resistance (61). The L1198F mutation was recently reported to exhibit resistance to lorlatinib mainly by interfering with drug binding through spatial site block. It has also been reported that L1198F mutation enhances the binding of crizotinib, reduces the effect of C1156Y and enhances susceptibility to crizotinib resistance (62). However, as for how to overcome L1198F mutation, the clinical efficacy and resistance mechanisms of lorlatinib need to be elucidated.

Known mechanisms of resistance include point mutations, fusion gene amplification and bypass signaling through the activation of other oncogenes (Fig. 2) (63), and AMPK, which is closely associated with *STK11* mutation and is one of the important pathways in the mechanism of *ALK* inhibitor resistance (30).

3. Current research progress on *STK11*

Function of *STK11*. *STK11* is considered an important tumor-suppressor gene with a wide range of metabolic functions (64). It encodes the serine/threonine kinase liver kinase B1 (*LKB1*), which activates a family of 12




Figure 2. Mechanisms of resistance to ALK inhibitors. ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein like protein 4; AMPK, AMP-activated protein kinase; MEK, MAP kinase-ERK kinase; ERK, extracellular signal-regulated kinase.

downstream kinases, including AMPK, and plays a role in essential biological functions, including cellular energy regulation (65). It is also involved in several physiological processes, including the regulation of cellular metabolism, cell polarity and DNA damage response (65,66). Tumor cells with inactivated or lost *STK11* are unable to activate adenosine monophosphate-activated protein kinases, and are therefore particularly vulnerable to energy stress states (67). *STK11* inactivation was initially identified in human tumors associated with Peutz-Jeghers genetic syndrome (68). *STK11* also negatively regulates mTOR signaling through its substrate AMPK, and *STK11* loss leads to the aberrant activation of mTOR in a variety of tissues. mTOR inhibitor everolimus has been shown to be effective (69,70). *STK11/LKB1* loss of function has been found in several cancer types, mainly through somatic alterations in the *STK11* gene, such as nonsense mutations, loss of heterozygosity, insertions, intragenic deletions or chromosomal deletions (71-79), while in Asian populations, *STK11* is mainly inactivated through focal deletions (80,81). Although *STK11* is inactivated by a large spectrum of truncating mutations and behaves like a tumor-suppressor gene in different tumor models through mTOR repression (77,82,83), recent studies have shown that *STK11* may also acquire oncogenic properties. Subsequently, somatic *STK11* mutations have been reported in other cancer types (69), including NSCLC (71,84,85). It has now been demonstrated that the loss of *LKB1* affects tumor progression through energy metabolism, cytokine inhibition, tumor immunosuppression and altered cell viability (86-90). Several types of tumors exhibit aberrant mutations in the *STK11* gene. For example, *STK11* deletion in cervical cancer and melanoma is associated with extensive and high-grade metastasis, and a heterozygous deletion of the *STK11* locus in primary breast cancer is associated with metastasis (91,92). *STK11*-mutant lung cancer constitutes a genetic subgroup of aggressive NSCLC with an *in vitro* inhibition of mitogen-activated protein kinase and mTOR signaling-increased sensitivity (93). *STK11* abnormalities have also been associated with cancer-related immune

dysfunction. For example, *STK11*-mutant lung cancer suppresses immune surveillance responses (94) and *STK11* deficiency decreases PD-L1 expression (95).

***STK11* and NSCLC.** *STK11* is one of the most commonly mutated genes in lung adenocarcinoma, and the *LKB1* protein encoded by the *STK11* gene is the second most common tumor suppressor in NSCLC, with mutations or genomic loss occurring in 17-23% of NSCLC cases (84,96,97). In lung cancer, the short *STK11* isoform, lacking 124 N-terminal amino acids, is defined as an oncogene (98). Indeed, it has been shown that cytoplasmic *STK11* interacts with estrogen receptor (ER) α /SRC/PI3K to stimulate the AKT pathway and is associated with a shorter survival (99). These findings suggested that *STK11* may play a tumor-suppressor or oncogene function. This dual mechanism may explain the lack of a clear association between *STK11* alterations and prognosis in lung cancer (100). *In vitro* studies have shown that *STK11* inactivation increases the motility and invasiveness of lung cancer, and facilitates epithelial-to-mesenchymal transition (EMT) in lung cancer, thus enhancing metastatic potential (101,102). In addition, it was shown that *STK11/LKB1* inactivation promotes cancer cell growth and survival through the upregulation of hypoxia-inducible factor 1 (HIF-1). The inactivation of *STK11/LKB1* in lung cancer cells leads to the upregulation of mTOR signaling, providing a growth advantage associated with mitochondrial dysfunction, due to autophagic injury (103,104). The aberrant activation of the PI3K/AKT/mTOR pathway has been identified in 90% of lung adenocarcinomas and 40% of squamous cell carcinomas (105). The PI3K/AKT/mTOR signaling pathway is mainly activated by receptor tyrosine kinases [e.g. epidermal growth factor receptor (EGFR), insulin-like growth factor receptor 1 (IGFR1), vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR)] and is involved in a variety of biological functions, such as proliferation, differentiation, survival, adhesion, motility, invasion and cellular metabolism (106,107). In addition to the activation of the PI3K/AKT/mTOR pathway by growth factors and insulin, different nutritional and environmental signals,

Table II. Chemotherapy and immunotherapy for *STK11* mutation status in NSCL.

Variable	OS (month)		PFS (month)	
	STK11m	STK11wt	STK11m	STK11wt
Chemotherapy (130)				
First-line	11.7	18.9	4.5	6.1
Second-line	13.1	15.2	4.2	4.5
Immunotherapy (131)				
First-line	14.2	20.1	4.1	5.4
Second-line	6.6	13.6	2.2	3.1

NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; *STK11*, serine/threonine kinase 11; *STK11m*, *STK11* mutation; *STK11wt*, *STK11* wild-type.

such as high levels of adenosine triphosphate (ATP), oxygen and elevated serum amino acid levels can also increase the activity of mTOR complex 1 (mTORC1). By contrast, intracellular and environmental stress signals, such as low ATP levels, hypoxia and DNA damage, inhibit mTORC1 activity mainly through AMPK activation (106). mTOR pathway activation has been found to be associated with poor clinical outcomes, invasiveness and metastasis (108-111). It is important to highlight that *LKB1*, encoded by *STK11*, is also associated with AMPK, and that *LKB1*/AMPK may counteract oxidative stress by inhibiting the synthesis of nicotinamide adenine dinucleotide phosphate (NADPH)-consuming fatty acids and increasing the oxidation of NADPH-producing fatty acids (112). At the same time, activated AMPK phosphorylates and activates the transcription factor nuclear related factor 2 (NRF2) (113). NRF2 then activates the transcription of antioxidant genes involved in NADPH production. High NADPH levels, together with autophagy, protect *LKB1*-savvy cancers from oxidative stress and reactive oxygen species (ROS)-induced chemotherapy (cisplatin, paclitaxel and adriamycin) (114). Thus, the activation of NRF2 is associated with more aggressive lung cancers and reduced patient survival (115). Of note, the activation of the *LKB1*/autophagy pathway enables circulating tumor cells to resist loss-of-nest apoptosis (116). Thus, cells lacking *LKB1* undergo apoptosis in response to metabolic stress because they are unable to respond to energy deficiency and restore homeostasis *in vivo* (117). The regulation of *STK11* expression and its role in cancer cell proliferation remains highly complex (118). For example, recent research has shown that asparagine and aspartic acid can regulate AMPK-mediated *p53* activation by physically binding to *LKB1* and regulating *LKB1* activity. *P53* has been reported to control cell survival by generating an auto-amplifying loop through asparagine-aspartate-mediated *LKB1*-AMPK signaling to regulate asparagine metabolism (118). In lung cancer, *STK11*/*LKB1* alterations are the only marker significantly associated with PD-L1 negativity in patients with high/medium tumor mutation burden (TMB) (119). Both elevated TMB and increased PDL1 expression are associated with IO response (120,121). Kelch like ECH associated protein 1 (KEAP1) mutations or double allelic deletions are enriched in patients with *LKB1*-mutant NSCLC tumors. NRF2 is a transcriptional factor and KEAP1

is a negative regulator of NRF2 that binds to the antioxidant response element on DNA and initiates the transcription of several genes involved in the regulation of redox homeostasis and cellular detoxification (122). Clinical studies have shown that in *KRAS*-driven NSCLC, *STK11* mutations leading to loss of function are associated with resistance to anti-programmed death 1 (PD-1) monoclonal antibody therapy, but the molecular mechanisms of pathogenesis are not yet clear (123). Despite some uncertainties, *STK11* functional status is emerging as a reliable biomarker for predicting a lack of response to anti-PD-1 therapy in NSCLC patients. It has been reported in the literature that *STK11* is significantly and significantly associated with decreased survival in meningiomas (124). Although the evidence on the biological role of *STK11* is not sufficient, its prognostic significance in advanced NSCLC needs to be confirmed; clarifying the role of *STK11* will facilitate the analysis of *STK11* mutational status, which may also provide more options for targeted therapy and IO (125). The role and significance of *STK11* in NSCLC needs to be further explored.

Current *STK11* mutation therapies for NSCLC. Cancer typically evades immune surveillance by aberrantly expressing immune checkpoints (e.g. PD-1) that isolate tumor cells from the host immune system. Immune blockade using monoclonal antibodies against the immune checkpoint PD-1 and its primary ligand PD-L1 can greatly improve survival in advanced NSCLC, with the greatest impact in patients with stage III and first-line stage IV lung cancer (126-128). However, in patients with other types, the response rate was just 20% (129). In a retrospective cohort study, data from the Clinico-Genomic Database were used to identify patients with metastatic NSCLC who received first-line IO (alone or in combination) or chemotherapy in routine clinical practice. The results suggested that in NSCLC, patients with *STK11* mutation (*STK11m*) exhibit poorer overall survival (OS) and PFS compared with patients with *STK11* wild-type (*STK11wt*) receiving IO or chemotherapy. Survival outcomes analyzed by treatment line and type showed that OS and PFS were worse in the IO treatment group for *STK11m* vs. *STK11wt* (Table II) (130). The results of the study were not optimistic, which further suggested that *STK11* mutations reduce the

survival rate of patients with NSCLC. Most importantly, it is unclear whether *STK11* can be used as a predictive biomarker to guide treatment selection, and prospective evaluation is still lacking. Therefore, immunotherapy should not be administered to patients with *STK11*-mutated tumors at the present time (131). At the same time, it has also been reported that *LKB1* encoded by the *STK11* gene may be associated with radioresistance in patients, and several previous studies have shown the role of *LKB1* expression in regulating the response to radiotherapy, based on preclinical experiments (132-134). However, to the best of our knowledge, there are no clinical trials on *STK11* mutations, so a comprehensive evaluation of patients with *STK11* mutations in NSCLC could not be performed.

4. Conclusions and perspectives

Both *STK11* and *ALK* can regulate tumor proliferation and growth through the mTOR pathway, and *STK11* can be oncogenic in NSCLC through the AMPK pathway, which is included in the mechanism of drug resistance in patients with *ALK*-positive NSCLC. mTOR signaling is known to be a master regulator of homeostasis and to integrate various environmental signals to regulate cell growth, proliferation and metabolism. The deregulation of mTOR signaling, particularly its overactivation, is frequent in human cancer. Recent advances in molecular profiling have identified certain genes involved in encoding the mTOR pathway, including *STK11*, *PIK3CA*, *PTEN* and *RPTOR* independent companion of MTOR complex 2 (RICTOR), whose amplification or mutation induces mTOR pathway activation. AMPK is a central metabolic sensor that coordinates cell growth and energy balance. In terms of oncogenesis, *LKB1* (mentioned previously) can directly phosphorylate and activate AMPK; therefore, in cells with *LKB1* mutations, the AMPK protein is oxidized and inactivated, leading to cell death. In terms of drug resistance, if the AMPK pathway is abnormally regulated, patients with *ALK*-positive NSCLC then become resistant to the drug.

In conclusion, *STK11* plays an important role in the treatment and drug resistance of patients with *ALK*-positive NSCLC. Although there is no definitive evidence on how *STK11* affects the prognosis of *ALK*-positive patients with NSCLC, the results of this review showed that *STK11* mutations may reduce the survival of *ALK*-positive NSCLC patients.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Hubei Province Health and Family Planning Scientific Research Project (grant nos. WJ2019-21) to NL.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

XCP and JC contributed to the design of this review. WZ, MW, MXM and ZQY reviewed the references. WZ, JC and XCP wrote the manuscript. WZ, LDY, YYC and NL designed and produced the tables and figures. YYC and NL revised the manuscript critically for important intellectual content. NL acquired the funding. YHY analyzed the data and designed the figures. LDY put a lot of effort into revising the manuscript and is listed as co-first author. Data authentication is not applicable. All authors read and approved the manuscript for publication.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. *Nat Rev Cancer* 17: 637-658, 2017.
2. Ye Z, Huang Y, Ke J, Zhu X, Leng S and Luo H: Breakthrough in targeted therapy for non-small cell lung cancer. *Biomed Pharmacother* 133: 111079, 2021.
3. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc* 83: 584-594, 2008.
4. Yang L, Li N, Wang M, Zhang YH, Yan LD, Zhou W, Yu ZQ, Peng XC and Cai J: Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review). *Oncol Rep* 46: 182, 2021.
5. Brueckl WM, Ficker JH and Zeitler G: Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). *BMC Cancer* 20: 1185, 2020.
6. Imyanitov EN, Iyevleva AG and Levchenko EV: Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. *Crit Rev Oncol Hematol* 157: 103194, 2021.
7. Liu J, Li D, Luo H and Zhu X: Circular RNAs: The star molecules in cancer. *Mol Aspects Med* 70: 141-152, 2019.
8. Guo B, Li D, Du L and Zhu X: piRNAs: Biogenesis and their potential roles in cancer. *Cancer Metastasis Rev* 39: 567-575, 2020.
9. Gerlinger M: Targeted drugs ramp up cancer mutability. *Science* 366: 1452-1453, 2019.
10. Liang G, Fan W, Luo H and Zhu X: The emerging roles of artificial intelligence in cancer drug development and precision therapy. *Biomed Pharmacother* 128: 110255, 2020.
11. Li S, Zhang Z, Lai WF, Cui L and Zhu X: How to overcome the side effects of tumor immunotherapy. *Biomed Pharmacother* 130: 110639, 2020.
12. Cecccon M, Mologni L, Bisson W, Scapozza L and Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. *Mol Cancer Res* 11: 122-132, 2013.
13. Toyokawa G, Hirai F, Inamasu E, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Seto T, Takenoyama M and Ichinose Y: Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. *J Thorac Oncol* 9: e86-e87, 2014.
14. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, *et al*: Molecular mechanisms of resistance to first- and second-generation ALK Inhibitors in ALK-rearranged lung cancer. *Cancer Discov* 6: 1118-1133, 2016.
15. Toyokawa G and Seto T: Updated evidence on the mechanisms of resistance to ALK Inhibitors and strategies to overcome such resistance: Clinical and preclinical data. *Oncol Res Treat* 38: 291-298, 2015.

16. Costa DB: Clinical development and approval of second generation ALK inhibitors for ALK-rearranged lung cancer. *Transl Lung Cancer Res* 3: 373-375, 2014.
17. Roskoski R Jr: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. *Pharmacol Res* 121: 202-212, 2017.
18. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, *et al*: Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 370: 1189-1197, 2014.
19. Rothschild SI: New treatment options for ALK+ advanced non-small-cell lung cancer: Critical appraisal of ceritinib. *Ther Clin Risk Manag* 12: 735-741, 2016.
20. Rossi A: Alectinib for ALK-positive non-small-cell lung cancer. *Expert Rev Clin Pharmacol* 9: 1005-1013, 2016.
21. Kong X, Pan P, Sun H, Xia H, Wang X, Li Y and Hou T: Drug discovery targeting anaplastic lymphoma kinase (ALK). *J Med Chem* 62: 10927-10954, 2019.
22. Qian M, Zhu B, Wang X and Liebman M: Drug resistance in ALK-positive non-small cell lung cancer patients. *Semin Cell Dev Biol* 64: 150-157, 2017.
23. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, *et al*: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 448: 561-566, 2007.
24. Katayama R, Lovly CM and Shaw AT: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine. *Clin Cancer Res* 21: 2227-2235, 2015.
25. Morales La Madrid A, Campbell N, Smith S, Cohn SL and Salgia R: Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. *Target Oncol* 7: 199-210, 2012.
26. Shaw AT and Solomon B: Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res* 17: 2081-2086, 2011.
27. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelman GO, Capelletti M, *et al*: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. *Cancer Res* 70: 9827-9836, 2010.
28. Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, *et al*: Establishment of a conditional transgenic mouse model recapitulating EML4-ALK-positive human non-small cell lung cancer. *J Thorac Oncol* 12: 491-500, 2017.
29. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, *et al*: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res* 14: 6618-6624, 2008.
30. Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C and Chiarle R: Tumor resistance against ALK-targeted therapy-where it comes from and where it goes. *Cancers (Basel)* 10: 62, 2018.
31. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, *et al*: In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. *Nature* 516: 423-427, 2014.
32. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, *et al*: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res* 15: 5216-5223, 2009.
33. Gristina V, La Mantia M, Iacono F, Galvano A, Russo A and Bazan V: The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer. *Pharmaceuticals (Basel)* 13: 474, 2020.
34. Du X, Shao Y, Qin HF, Tai YH and Gao HJ: ALK-rearrangement in non-small-cell lung cancer (NSCLC). *Thorac Cancer* 9: 423-430, 2018.
35. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, *et al*: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. *Lancet Oncol* 13: 1011-1019, 2012.
36. Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, *et al*: Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. *ESMO Open* 2: e000219, 2017.
37. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, *et al*: Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. *Cancer Res Treat* 50: 691-700, 2018.
38. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, *et al*: Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. *J Clin Oncol* 36: 2251-2258, 2018.
39. Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, *et al*: Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol* 17: 452-463, 2016.
40. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, *et al*: Multicenter phase ii study of whole-body and intracranial activity with ceritinib in patients With ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2. *J Clin Oncol* 34: 2866-2873, 2016.
41. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, *et al*: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. *Lancet* 389: 917-929, 2017.
42. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, *et al*: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. *Lancet* 390: 29-39, 2017.
43. Pérol M, Pavlakakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, *et al*: Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. *Lung Cancer* 138: 79-87, 2019.
44. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakakis N, de Marinis F, *et al*: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. *J Thorac Oncol* 14: 1233-1243, 2019.
45. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, *et al*: Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-IL Trial. *J Clin Oncol* 38: 3592-3603, 2020.
46. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, *et al*: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 Study. *Lancet Oncol* 19: 1654-1667, 2018.
47. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, *et al*: The ALK inhibitor crizotinib overcomes crizotinib resistance in non-small cell lung cancer. *Cancer Discov* 4: 662-673, 2014.
48. Xia B, Nagasaka M, Zhu VW, Ou SI and Soo RA: How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). *Transl Lung Cancer Res* 9: 2521-2534, 2020.
49. Werner MT, Zhao C, Zhang Q and Wasik MA: Nucleophosmin-anaplastic lymphoma kinase: The ultimate oncogene and therapeutic target. *Blood* 129: 823-831, 2017.
50. Tse BC, Said BI, Fan ZJ, Hueniken K, Patel D, Gill G, Liang M, Razooqi M, Brown MC, Sacher AG, *et al*: Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: A prospective real-world assessment. *Curr Oncol* 27: e552-e559, 2020.
51. Castellanos EH and Horn L: Re-Evaluating progression in an era of progress: A review of first- and second-line treatment options in anaplastic lymphoma kinase-positive non-small cell lung cancer. *Oncologist* 21: 755-761, 2016.
52. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, *et al*: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med* 383: 1328-1339, 2020.
53. Hallberg B and Palmer RH: The role of the ALK receptor in cancer biology. *Ann Oncol* 27 (Suppl 3): iii4-iii15, 2016.

54. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, *et al*: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 363: 1734-1739, 2010.
55. Azam M, Seeliger MA, Gray NS, Kuriyan J and Daley GQ: Activation of tyrosine kinases by mutation of the gatekeeper threonine. *Nat Struct Mol Biol* 15: 1109-1118, 2008.
56. Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, *et al*: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. *Clin Cancer Res* 17: 7394-7401, 2011.
57. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, *et al*: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 71: 6051-6060, 2011.
58. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, *et al*: Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. *Clin Cancer Res* 20: 5686-5696, 2014.
59. Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, *et al*: Protocol design for the bench to bed trial in alectinib-refractory non-small-cell lung cancer patients harboring the EML4-ALK fusion gene (ALRIGHT/OLCSG1405). *Clin Lung Cancer* 17: 602-605, 2016.
60. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethson K, Shaw AT, Gettinger S, Cosper AK, *et al*: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 3: 75ra26, 2011.
61. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, *et al*: PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. *Cancer Cell* 28: 70-81, 2015.
62. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, *et al*: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. *N Engl J Med* 374: 54-61, 2016.
63. Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, *et al*: Results of PROFILE 1029, a phase iii comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. *J Thorac Oncol* 13: 1539-1548, 2018.
64. Krishnamurthy N, Goodman AM, Barkauskas DA and Kurzrock R: STK11 alterations in the pan-cancer setting: Prognostic and therapeutic implications. *Eur J Cancer* 148: 215-229, 2021.
65. Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga A, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, *et al*: Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. *Cell Rep* 33: 108444, 2020.
66. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, *et al*: STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. *Cancer Discov* 8: 822-835, 2018.
67. Gowans GJ, Hawley SA, Ross FA and Hardie DG: AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab* 18: 556-566, 2013.
68. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Höglund P, *et al*: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 391: 184-187, 1998.
69. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haafte G, Mironenko T, Santarius T, Stevens C, Stratton MR and Futreal PA: LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. *Br J Cancer* 100: 370-375, 2009.
70. Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, *et al*: Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant. *Cold Spring Harb Mol Case Stud* 3: a000778, 2017.
71. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. *Cancer Res* 62: 3659-3662, 2002.
72. Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N and Depinho RA: Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. *Mol Cell Biol* 28: 2414-2425, 2008.
73. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, *et al*: Somatic LKB1 mutations promote cervical cancer progression. *PLoS One* 4: e5137, 2009.
74. Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS, Roy Chowdhuri S, Shakoori A, Dracheva T, Hong KM, *et al*: Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. *Oncogene* 30: 3784-3791, 2011.
75. Lee SM, Choi JE, Na YK, Lee EJ, Lee WK, Choi YY, Yoon GS, Jeon HS, Kim DS and Park JY: Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers. *Lung Cancer* 81: 194-199, 2013.
76. Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T, Ohguchi Y, Birrer MJ and Teixeira JM: Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. *Carcinogenesis* 35: 546-553, 2014.
77. Li J, Liu J, Li P, Mao X, Li W, Yang J and Liu P: Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. *J Exp Clin Cancer Res* 33: 70, 2014.
78. Yang JY, Jiang SH, Liu DJ, Yang XM, Huo YM, Li J, Hua R, Zhang ZG and Sun YW: Decreased LKB1 predicts poor prognosis in pancreatic ductal adenocarcinoma. *Sci Rep* 5: 10575, 2015.
79. Zhang W, Yin L, Song G, Han X, Yin Z and Luo D: LKB1 loss cooperating with BRAFV600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway. *Oncotarget* 8: 113847-113857, 2017.
80. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna JD and Yokota J: Prevalence and specificity of LKB1 genetic alterations in lung cancers. *Oncogene* 26: 5911-5918, 2007.
81. Fang R, Zheng C, Sun Y, Han X, Gao B, Li C, Liu H, Wong KK, Liu XY, Chen H and Ji H: Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. *J Thorac Oncol* 9: 254-258, 2014.
82. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, *et al*: LKB1 modulates lung cancer differentiation and metastasis. *Nature* 448: 807-810, 2007.
83. Liang J and Mills GB: AMPK: A contextual oncogene or tumor suppressor? *Cancer Res* 73: 2929-2935, 2013.
84. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 511: 543-550, 2014.
85. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, *et al*: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 150: 1107-1120, 2012.
86. Baas AF, Smit L and Clevers H: LKB1 tumor suppressor protein: PARTaker in cell polarity. *Trends Cell Biol* 14: 312-319, 2004.
87. Forcet C, Etienne-Manneville S, Gaude H, Fournier L, Debilly S, Salmi M, Baas A, Olschwang S, Clevers H and Billaud M: Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. *Hum Mol Genet* 14: 1283-1292, 2005.
88. Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, *et al*: LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. *Cancer Res* 79: 3251-3267, 2019.
89. Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, *et al*: STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. *Cancer Res* 76: 999-1008, 2016.

90. Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. *Nat Rev Cancer* 9: 563-575, 2009.
91. Shen Z, Wen XF, Lan F, Shen ZZ and Shao ZM: The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. *Clin Cancer Res* 8: 2085-2090, 2002.
92. Liu W, Monahan KB, Pfeifferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, *et al*: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. *Cancer Cell* 21: 751-764, 2012.
93. Sanchez-Cespedes M: A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. *Oncogene* 26: 7825-7832, 2007.
94. Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, *et al*: Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. *Oncogene* 35: 3209-3216, 2016.
95. Lamberti G, Sisi M, Andrini E, Palladini A, Giunchi F, Lollini PL, Ardizzoni A and Gelsomino F: The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? *Cancers (Basel)* 12: 3129, 2020.
96. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, *et al*: Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. *Cancer Discov* 7: 596-609, 2017.
97. Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH and Salgia R: Usefulness of circulating tumor DNA in identifying somatic mutations and tracking tumor evolution in patients with non-small cell lung cancer. *Chest* 160: 1095-1107, 2021.
98. Dahmani R, Just PA, Delay A, Canal F, Finzi L, Prip-Buus C, Lambert M, Sujobert P, Buchet-Poyau K, Miller E, *et al*: A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties. *Oncogene* 34: 2337-2346, 2015.
99. Bouchekioua-Bouzaghoul K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, *et al*: LKB1 when associated with methylated ER α is a marker of bad prognosis in breast cancer. *Int J Cancer* 135: 1307-1318, 2014.
100. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, *et al*: Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. *Br J Cancer* 99: 245-252, 2008.
101. Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T and Yokota J: Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. *Lung Cancer* 70: 136-145, 2010.
102. Yao YH, Cui Y, Qiu XN, Zhang LZ, Zhang W, Li H and Yu JM: Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells. *Chin J Cancer* 35: 50, 2016.
103. Momcilovic M and Shackelford DB: Targeting LKB1 in cancer-exposing and exploiting vulnerabilities. *Br J Cancer* 113: 574-584, 2015.
104. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, *et al*: LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. *Cancer Cell* 23: 143-158, 2013.
105. Dobashi Y, Watanabe Y, Miwa C, Suzuki S and Koyama S: Mammalian target of rapamycin: A central node of complex signaling cascades. *Int J Clin Exp Pathol* 4: 476-495, 2011.
106. Saxton RA and Sabatini DM: mTOR signaling in growth, metabolism, and disease. *Cell* 168: 960-976, 2017.
107. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. *Nat Rev Cancer* 9: 550-562, 2009.
108. Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W, Cao Y, Zhao S, Zhang W, Qiu Z, *et al*: Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. *J Exp Clin Cancer Res* 34: 126, 2015.
109. Krenetz I, Sebestyén A, Fábrián K, Márk Á, Moldvay J, Khoor A, Kopper L and Pápay J: Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. *Hum Pathol* 62: 66-73, 2017.
110. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T and Eguchi K: Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. *Clin Cancer Res* 8: 3046-3053, 2002.
111. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J and Travis WD: Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. *Clin Cancer Res* 16: 240-248, 2010.
112. Jeon SM, Chandel NS and Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature* 485: 661-665, 2012.
113. Joo MS, Kim WD, Lee KY, Kim JH, Koo JH and Kim SG: AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550. *Mol Cell Biol* 36: 1931-1942, 2016.
114. Ciccavese F, Zulato E and Indraccolo S: LKB1/AMPK pathway and drug response in cancer: A therapeutic perspective. *Oxid Med Cell Longev* 2019: 8730816, 2019.
115. Singh A, Daemen A, Nickles D, Jeon SM, Foreman O, Sudini K, Gnad F, Lajoie S, Gour N, Mitzner W, *et al*: NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes. *Clin Cancer Res* 27: 877-888, 2021.
116. Trapp EK, Majunke L, Zill B, Sommer H, Andergassen U, Koch J, Harbeck N, Mahner S, Friedl TWP, Janni W, *et al*: LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. *Mol Oncol* 11: 1508-1526, 2017.
117. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci USA* 101: 3329-3335, 2004.
118. Deng L, Yao P, Li L, Ji F, Zhao S, Xu C, Lan X and Jiang P: p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival. *Nat Commun* 11: 1755, 2020.
119. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther* 16: 2598-2608, 2017.
120. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, *et al*: Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid Tumors. *JAMA Oncol* 4: 1237-1244, 2018.
121. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, *et al*: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol* 31: 1023-1031, 2013.
122. Kobayashi A, Kang MI, Okawa H, Ohtsui M, Zenke Y, Chiba T, Igarashi K and Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. *Mol Cell Biol* 24: 7130-7139, 2004.
123. Donnelly LL, Hogan TC, Lenahan SM, Nandagopal G, Eaton JG, Lebeau MA, McCann CL, Sarasky HM, Hampel KJ, Armstrong JD, *et al*: Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers. *Carcinogenesis* 42: 1428-1438, 2021.
124. Gill CM, Loewenstern J, Rutland JW, Arib H, Pain M, Umphlett M, Kinoshita Y, McBride RB, Bederson J, Donovan M, *et al*: STK11 mutation status is associated with decreased survival in meningiomas. *Neurol Sci* 41: 2585-2589, 2020.
125. Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L and Besse B: LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. *Lung Cancer* 112: 62-68, 2017.
126. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, *et al*: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med* 373: 1627-1639, 2015.
127. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, *et al*: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. *Lancet* 389: 255-265, 2017.

128. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, *et al*: Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial. *Ann Oncol* 30: 281-289, 2019.
129. Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F and Paz-Ares L: Biological therapies in nonsmall cell lung cancer. *Eur Respir J* 49: 1601520, 2017.
130. Shire NJ, Klein AB, Golozar A, Collins JM, Fraeman KH, Nordstrom BL, McEwen R, Hembrough T and Rizvi NA: STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. *PLoS One* 15: e0238358, 2020.
131. Mograbi B, Heeke S and Hofman P: The Importance of STK11/LKB1 assessment in non-small cell lung carcinomas. *Diagnostics (Basel)* 11: 196, 2021.
132. Herter-Sprie GS, Korideck H, Christensen CL, Herter JM, Rhee K, Berbeco RI, Bennett DG, Akbay EA, Kozono D, Mak RH, *et al*: Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. *Nat Commun* 5: 5870, 2014.
133. He Q, Li J, Dong F, Cai C and Zou X: LKB1 promotes radioresistance in esophageal cancer cells exposed to radiation, by suppression of apoptosis and activation of autophagy via the AMPK pathway. *Mol Med Rep* 16: 2205-2210, 2017.
134. Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, *et al*: Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer. *Clin Cancer Res* 24: 5744-5756, 2018.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.